Veterinary Endocrinology Market – By Treatment Type, By Disease Type, By Animal Type, By End Use – Global Forecast, 2025 - 2034

Veterinary Endocrinology Market Size

The global veterinary endocrinology market was valued at USD 414.5 million in 2024. The market is expected to grow from USD 437.5 million in 2025 to USD 770.3 million in 2034, at a CAGR of 6.5% from 2025 to 2034.

The market is experiencing steady growth, driven by the increasing prevalence of endocrine disorders such as diabetes mellitus, Cushing’s disease, and Addison’s disease in companion animals. Rising pet ownership, the humanization of pets, and the availability of advanced veterinary point of care diagnostics are further fueling market expansion.
 

Veterinary endocrinology is a specialized segment of animal healthcare focused on the diagnosis, treatment and management of hormonal disorders in animals, especially in companion animals. Key players such as Zoetis, Dechra Pharmaceuticals, Elanco, Boehringer Ingelheim, and Virbac dominate the market with leading products including ProZinc, Percorten-V, and Synovex, supported by global distribution networks.
 

The market grew from USD 352.6 million in 2021 to USD 392.2 million in 2023, propelled by technological innovations that enhance diagnostic speed and accuracy. For example, in October 2023, The Royal Veterinary College collaborated with Dechra Veterinary Products to develop a data-driven app that supports the diagnosis and treatment of endocrine disorders in pets. The increasing incidence of obesity among companion animals is also contributing to higher rates of diabetes and related disorders. According to the American Veterinary Medical Association, diabetes affects approximately 1 in 300 dogs and 1 in 230 cats in the U.S., creating greater demand for preventive diagnostics, weight management programs, and hormonal therapies.  
 

Pharmaceutical companies are actively investing in R&D to improve drug efficacy, safety, and ease of administration. In August 2023, Boehringer Ingelheim secured FDA approval for Senvelgo (velagliflozin oral solution), a once-daily treatment for feline diabetes. Similarly, the approval of SGLT2 inhibitors for newly diagnosed feline diabetes underscores the growing innovation in endocrinology therapeutics.
 

The market’s momentum is further supported by advanced drug delivery systems, enhancing treatment compliance and outcomes in both companion and livestock animals. Additionally, the approval of Percorten-V by Novartis Animal Health in May 2022 marked a milestone as the first FDA-approved treatment for Addison’s disease in dogs.
 

Emerging economies, particularly in Asia-Pacific and Latin America, are witnessing increasing investments in veterinary infrastructure, further strengthening the market outlook. Long-term endocrine therapies such as insulin, levothyroxine, and mitotane are expected to see sustained demand, reinforcing the growth trajectory of the veterinary endocrinology market.
 

Veterinary Endocrinology Market Trends

• The market is undergoing significant transformation driven by both macro- and micro-level trends. A surge in pet ownership, particularly among urban and high-income households, has amplified the demand for specialized veterinary care.
   
• As of 2025, 94 million U.S. households own a pet, according to the American Pet Products Association, reflecting a robust consumer base for endocrine therapies, especially with the rising prevalence of conditions such as diabetes, Cushing’s disease, and hypothyroidism.
   
• The growing focus on preventive veterinary care and the adoption of portable point-of-care diagnostic devices are reducing delays in treatment and improving compliance. These trends are not only enhancing clinical outcomes but are also expanding access to endocrine treatments in remote or resource-limited settings.
   
• Agencies such as the FDA-CVM and EMA are streamlining conditional approval pathways for critical endocrine treatments, particularly those addressing rare conditions. A notable example is the October 2024 launch of Trilotab by Virbac, the first chewable, flavored, and divisible Trilostane tablet designed for the treatment of Cushing’s Syndrome in dogs. Its flexible dosing design improves customization and treatment adherence.
   
• Increasing demand for precision dosing and breed-specific hormone therapies, supported by advances in genetic testing, is reshaping treatment protocols. Pharmaceutical companies are also investing in combination therapies, such as hormone replacement combined with anti-inflammatory agents for adrenal disorders, thereby enhancing treatment outcomes and compliance for complex conditions.
   
• The market is witnessing the convergence of technologies, including thyroxine biosimilars, rapid diagnostics, and smart drug delivery systems, which collectively improve therapeutic efficacy and convenience. R&D efforts are also focused on developing cleaner formulations, free from harmful preservatives and allergens, to ensure safer long-term endocrine care for companion animals.
   

Veterinary Endocrinology Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

 In 2021, the global market was valued at USD 352.6 million. The following year, it saw a slight increase to USD 371.6 million, and by 2023, the market further climbed to USD 392.2 million.
 

Based on treatment type, the global market is divided into pharmacological treatment and non-pharmacological treatment. In 2024, the pharmacological treatment segment accounted for 76.5% of the global market, driven by the high prevalence of endocrine disorders in companion animals, technological advancements in drug formulation, and increased awareness and early diagnosis of these conditions. This segment is projected to reach USD 596.4 million by 2034, growing at a CAGR of 6.6% over the forecast period. While pharmacological therapies dominate, the non-pharmacological treatment segment is also gaining traction, projected to grow at a CAGR of 6.1% over the forecast period.
 

• Pharmacological treatments are sub-segmented by drug type, including insulin and antidiabetic agents, thyroid hormone replacements, adrenal hormone modulators, reproductive hormones, and other related therapies.
   
• The pharmacological segment continues to lead the market due to its cost-effectiveness for long-term disease management, particularly when compared to surgical or advanced biotechnological interventions.
   
• Chronic endocrine disorders such as diabetes mellitus, hypothyroidism, Cushing’s disease, and Addison’s disease necessitate sustained therapeutic regimens, making pharmacological approaches the preferred option.
   
• Continuous innovation in drug delivery mechanisms is significantly enhancing treatment compliance and effectiveness. Sustained-release formulations, chewable tablets, and transdermal gels for both companion and livestock animals are making treatments more user-friendly and effective. For instance, Elanco’s ProZinc (insulin for cats and dogs) and Dechra’s Zycortal (desoxycorticosterone pivalate for Addison’s disease) are key examples of such innovations driving market expansion.
   

Based on disease type, the veterinary endocrinology market is classified into diabetes mellitus, hypothyroidism, hyperthyroidism, Cushing's syndrome, Addison's disease, reproductive disorders and other disease types. The diabetes mellitus disease type segment dominated the market in 2024 and is growing with a CAGR of 6.4% during the forecast period.
 

• Obesity remains the leading risk factor for diabetes in pets, especially dogs and cat, fueling diagnostic and therapeutic demand. According to the Association for Pet Obesity Prevention (APOP), approximately 59% of cats and 53% of dogs in the U.S. were classified as overweight. Overfeeding and sedentary lifestyles increase insulin resistance, which in turn drives the need for veterinary diabetic care.
   
• The market is also benefitting from advancements in diabetes management technologies, including continuous glucose monitors (CGMs) and long-acting insulin analogs, which have significantly improved disease monitoring and control.
   
• In 2024, hypothyroidism emerged as the second-largest disease segment, accounting for 19.5% of the market share. Market growth is primarily driven by the increasing incidence of canine hypothyroidism and growing awareness through veterinary education, diagnostic improvements, and pet wellness campaigns.
   
• According to U.S. data, the prevalence of canine hypothyroidism is 1.9%, necessitating lifelong treatment and regular monitoring. This trend supports the growing demand for thyroid hormone replacement therapies, especially levothyroxine-based products.
   

Based on animal type, the veterinary endocrinology market is bifurcated into companion animals and livestock animals. The companion animals’ segment was anticipated to be worth USD 330.1 million in 2024 and is expected to grow at 6.6% CAGR during the forecast period. The companion animals’ segment is further bifurcated into dogs, cats, and other companion animals. 
 

• The growing humanization of pets is a key driver of market growth. Pet owners increasingly view animals as family members, prompting higher spending on veterinary care, particularly for chronic and endocrine-related conditions.
   
• According to the American Pet Products Association, pet-related spending in the U.S. reached USD 152 billion in 2024, up from USD 147 billion in 2023, indicating strong growth in demand for services such as hormone therapy, routine diagnostics, and blood glucose monitoring.
   
• The rise in veterinary training programs and specialization in internal medicine and endocrinology has strengthened clinical capabilities in managing complex endocrine cases in companion animals. Enhanced diagnostic accuracy and availability of targeted treatments are contributing to better disease outcomes and increased adoption of endocrine therapeutics.
   
• While the companion animal segment leads the market, the livestock segment is poised for considerable growth, driven by the rapid expansion of commercial farming, particularly in developing countries such as India, China, and Brazil.
   
• The growing pressure to maximize productivity and reproductive efficiency in livestock is compelling farmers to invest in metabolic and reproductive hormone therapies, fueling robust growth in this segment.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the veterinary endocrinology market is classified into veterinary hospitals and clinics, retail veterinary pharmacies, and other end users. The veterinary hospitals and clinics segment dominated the market in 2024 and is expected to reach USD 518.4 million within the forecast period. 
 

• Veterinary hospitals and clinics are rapidly integrating telemedicine and remote monitoring technologies to support the management of chronic endocrine conditions, particularly diabetes mellitus.
   
• According to the National Institute of Medicine, telehealth adoption in small animal veterinary practices rose from 12% pre-pandemic to 38% in general and specialty hospitals. This shift reflects veterinarians’ commitment to improving accessibility and continuity of care while adapting to client expectations.
   
• The emergence and growth of corporate veterinary clinic networks, such as Banfield, VCA, and MaxPetZ, have contributed to the standardization of endocrinology services across multiple locations. These organizations are setting benchmarks in endocrine diagnostics and chronic care management, ensuring uniform quality and improved patient outcomes.
   
• Veterinary clinics also serve as primary sites for clinical trials and product development related to endocrine drugs and diagnostics. Their active participation in R&D collaborations positions them at the forefront of emerging therapeutic technologies, further enhancing their ability to deliver advanced, evidence-based treatments.

Looking for region specific data?

Download Free PDF

The North America veterinary endocrinology market dominated the global market with a market share of 41.3% in 2024.
 

The U.S. market alone grew from USD 132.7 million in 2021 to USD 155.1 million in 2024, driven by early adoption of continuous glucose monitoring (CGM) systems, telemedicine, enabled endocrine care, and a concentration of board-certified veterinary internists specialized in endocrinology.
 

• The regional growth is fueled by the high burden of endocrine disorders such as canine hypothyroidism and diabetes mellitus in cats and dogs.
   
• Growing pet obesity and aging populations are major contributors to this trend. For instance, Banfield Pet Hospital data indicates an 80% increase in diabetes among dogs over the past decade. This has translated into rising demand for advanced hormonal therapies, diagnostic assays, and insulin management tools tailored for veterinary use.
   
• The strong presence of pharmaceutical leaders like Zoetis, Elanco, Merck Animal Health, and Boehringer Ingelheim, along with robust regulatory backing from the U.S. FDA-CVM, supports continual drug innovation and commercialization.
   

Europe veterinary endocrinology market accounted for USD 108.5 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The regional growth is propelled by an expanding small animal segment and a structured regulatory landscape led by the European Medicines Agency (EMA) and its Committee for Veterinary Medicinal Products (CVMP) body.
   
• Countries such as Germany, France, and the Netherlands are front-runners due to the widespread availability of specialty vet clinics and growing awareness about hormonal imbalances in companion animals.
   
• The high concentration of veterinarians across Europe, estimated at 328,000+ professionals by the Federation of Veterinarians of Europe, supports early detection, long-term treatment adherence, and better therapeutic outcomes.
   
• Germany dominates the European market, showcasing strong growth potential. The country is advancing diagnostic adoption for thyroid dysfunction, Cushing’s syndrome, and reproductive disorders through AI-integrated diagnostic platforms and hormone-level monitoring tools.
   

The Asia Pacific veterinary endocrinology market is anticipated to grow at the highest CAGR of 7.1% during the analysis timeframe.
 

• This growth is attributed to rising pet ownership, increasing awareness of chronic disease management in animals, and expanding access to veterinary care. For example, China recorded over 120 million pet dogs and cats in 2024, driving clinical demand for endocrine treatments such as long-acting insulin analogs and thyroid hormone replacements.
   
• Veterinary academic programs across India, China, and South Korea are also incorporating specialized training in endocrinology, supporting diagnostic accuracy and improving disease outcomes.
   
• Additionally, livestock-focused initiatives like India’s NADCP are enhancing metabolic and reproductive health in ruminants through hormone-based therapies, improving market uptake in the bovine endocrinology segment.   
   

Latin American veterinary endocrinology market, exhibiting remarkable growth during the analysis period.
 

• Urban centers in Brazil, Mexico, and Argentina are witnessing increasing caseloads of diabetes mellitus, Cushing’s disease, and thyroid disorders, prompting a rise in veterinary diagnostics and hormonal therapeutics.
   
• Meanwhile, the livestock segment benefits from precision farming practices aimed at improving reproductive efficiency via hormonal synchronization protocols.
   
• Public-private partnerships and veterinary outreach programs across rural areas are also raising awareness and encouraging early diagnosis of hormonal disorders, which supports long-term treatment adherence and market penetration.
   

The Middle East and Africa veterinary endocrinology market is expected to experience substantial growth in 2024.
 

• Government-backed animal health programs and the entry of multinational pharmaceutical firms are playing a pivotal role in improving access to diagnostic and therapeutic solutions for endocrine conditions.
   
• Countries such as South Africa, UAE, and Saudi Arabia are witnessing an uptick in pet ownership and demand for specialty veterinary services, including endocrinology consultations.
   
• The growing presence of veterinary academic centers and international collaborations is expected to bridge the gap in disease recognition and hormonal treatment delivery, thereby accelerating the region’s contribution to the global market.
   

Veterinary Endocrinology Market Share

The market is characterized by diverse players competing in the industry. The top 5 players such as Zoetis, Elanco Animal Health, Dechra Pharmaceuticals, Merck, and Boehringer Ingelheim account for approximately 75% of the market share in the moderately consolidated global market. These prominent players thrive through a combination of strategic initiatives, investing in research and development, to meet specific needs of veterinary endocrinology. The niche players or disruptors collectively hold a smaller portion of the market, primarily due to limited global reach or narrower product offerings.
 

The key players of the market are using competitive pricing strategies for pharmacological treatment which is intended to provide a more affordable option compared to non-pharmacological treatment. Players are also addressing market gaps by launching novel drug therapeutics, that offer significant advantages over conventional treatment plans.
 

Further, players in the industry are leveraging a multi-pronged strategic approach including acquisitions, partnerships, R&D investments, to reinforce their competitive positioning and respond to the rising demand for veterinary endocrinology globally. Zoetis leads in hormonal injectable and long-acting endocrine modulators, while Boehringer Ingelheim has gained traction via Vetoryl product for canine hyperadrenocorticism.
 

Veterinary Endocrinology Market Companies

Prominent players operating in the veterinary endocrinology industry are as mentioned below:

• Boehringer Ingelheim
• Dechra Pharmaceuticals
• Elanco Animal Health
• Kela Health
• Merck
• MedPharm Animal Health
• Med-Pharmex
• Nextmune
• Virbac
• Vivaldis Animal Health
• Zoetis
   
• Zoetis

Zoetis offer a well-established portfolio with its flagship products of ProZinc and Percorten-V. The company’s extensive global presence in the U.S., Latin America, and Europe with increasing investment in diagnostic tools help maintain its leadership in both hormonal therapy and monitoring.
 

• Dechra Pharmaceuticals

Dechra is expanding its footprint in the veterinary endocrinology market across Europe and North America, driven by its leading endocrine therapies such as Forthyron (for canine hypothyroidism) and Felimazole (for feline hyperthyroidism). With a dedicated focus on endocrine disorders, the company has secured a considerable share of the market.
 

• Boehringer Ingelheim

Boehringer Ingelheim is one of the key players in the market, leveraging its robust research infrastructure and existing global reach. The company emphasis on innovation, particularly in long-acting formulation and companion diagnostics.
 

• Elanco Animal Health

Elanco Animal Health offers Vetsulin, a well-established insulin therapy for diabetes mellitus in dogs and cats, giving it a solid foothold in the endocrine therapeutic space. Elanco provides affordable access and strategic partnerships with veterinary groups, making it a reliable and increasingly influential player in this segment.
 

Veterinary Endocrinology Industry News

• In June 2025, IDEXX Laboratories, Inc. announced the launch of the Catalyst Cortisol Test, which measures real-time quantitative cortisol concentrations to support the diagnosis of Addison's disease and diagnosis and management of Cushing's syndrome in dogs. IDEXX's Catalyst Cortisol Test is the third menu expansion in under a year for the Catalyst platform, further advancing the diagnostic capabilities available to veterinary practices at the point-of-care.
   
• In August 2024, Norbrook Inc., announced the release of Felanorm (methimazole) Oral Solution, the first FDA approved oral methimazole solution. The new oral solution is indicated for the treatment of hyperthyroidism in cats. It has the same safety, efficacy and indications as the pioneer tablets, but is in a much more convenient formulation for ease of administration.
   
• In October 2023, RVC collaborates with Dechra on veterinary endocrinology app for dogs. An endocrinology app has been created using the latest AI technology developed by RVC’s VetCompass team. The app will provide vets with a prediction of how likely a dog is to have Cushing’s syndrome based on its clinical signs and will also provide additional information on the treatment and monitoring of diseases such as Cushing’s and Addison’s.
   

The veterinary endocrinology market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Pharmacological treatment
  • By drug type
    • Insulin and antidiabetics
    • Thyroid hormone replacement
    • Adrenal hormone modulators
    • Reproductive hormones
    • Other drug types
  • By route of administration
    • Oral
    • Injectables
    • Topical
    • Other routes of administration
• Non-pharmacological treatment

Market, By Disease Type

• Diabetes mellitus
• Hypothyroidism
• Hyperthyroidism
• Cushing's syndrome
• Addison's disease
• Reproductive disorders
• Other disease types

Market, By Animal Type

• Companion animals
  • Dogs
  • Cats
  • Other companion animals
• Livestock animals
  • Cattle
  • Sheep and goats
  • Other livestock animals

Market, By End Use

• Veterinary hospitals and clinics
• Retail veterinary pharmacies
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE